D-二聚体作为COVID-19疾病严重程度的潜在生物标志物
本研究回顾性分析120例RT-PCR确诊的COVID-19患者的临床、影像和实验室数据,按临床严重程度分为非复杂/轻症或重症肺炎,按CT肺部受累面积分为0-30%或≥31%。结果显示63.3%(76/120)患者D-二聚体升高(>243 ng/ml),ICU重症肺炎住院患者平均D-二聚体为3144.50±1709.4 ng/ml(1643-8548)。D-二聚体与年龄、住院时长、肺部受累、纤维蛋白原、中性粒细胞计数、NLR和PLR呈正相关。ROC分析显示阈值370 ng/ml对肺部受累的敏感度74%、特异度77%。结论认为D-二聚体与结局相关,但需进一步研究确定其预后价值。
要点
- 120例COVID-19患者中63.3%(76/120)D-二聚体升高(>243 ng/ml)。
- ICU重症肺炎住院患者平均D-二聚体3144.50±1709.4 ng/ml(范围1643-8548)。
- D-二聚体与年龄、住院时长、肺部受累、纤维蛋白原、中性粒细胞计数、NLR、PLR正相关。
- ROC分析阈值370 ng/ml对肺部受累的敏感度74%、特异度77%。
- 原文结论:D-二聚体与结局相关,但需进一步研究确定预后价值。
适用人群与场景
- 120例经RT-PCR确诊的COVID-19患者,回顾性评估临床、影像和实验室数据。
- 按临床严重程度分为非复杂/轻症或重症肺炎;按CT肺部受累面积分为0-30%或≥31%。
诊断标准与关键阈值
- D-二聚体升高定义为>243 ng/ml,本研究中63.3%(76/120)患者符合。
- ROC分析中D-二聚体阈值370 ng/ml对肺部受累的敏感度74%、特异度77%。
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:回顾性研究;样本量120例;单中心(原文未明确中心数,按单中心处理)。
- 人群:RT-PCR确诊的COVID-19患者。
- 干预与对照:原文未提及(观察性研究,无干预对照)。
- 主要终点结果:D-二聚体升高(>243 ng/ml)占63.3%(76/120);ICU重症肺炎住院患者平均D-二聚体3144.50±1709.4 ng/ml(1643-8548);ROC阈值370 ng/ml对肺部受累敏感度74%、特异度77%。
- 关键次要终点:D-二聚体与年龄、住院时长、肺部受累、纤维蛋白原、中性粒细胞计数、NLR、PLR正相关;原文未提供具体相关系数或P值。
- 不良事件:原文未提及。
证据类型、等级与局限
- 证据类型:回顾性观察性研究(原文未明确标注证据等级或推荐强度)。
- 局限:回顾性设计、样本量120例、单中心(原文未明确中心数)、原文结论指出需进一步研究确定预后价值。
对床旁实践的改变
- 原文结论认为D-二聚体与COVID-19结局相关,但尚不能确定其预后价值,需进一步研究;原文未给出改变临床实践的具体推荐。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: This study seeks to determine the utility of D-dimer levels as a biomarker in determining disease severity and prognosis in COVID-19.
METHODS: Clinical, imaging and laboratory data of 120 patients whose COVID-19 diagnosis based on RT-PCR were evaluated retrospectively. Clinically, the severity of COVID-19 was classified as noncomplicated or mild or severe pneumonia. Radiologically, the area of affected lungs compatible with viral pneumonia in each patient's computed tomography was classified as either 0-30% or ≥ 31% of the total lung area. The D-dimer values and laboratory data of patients with COVID-19 were compared with inpatient status, duration of hospitalization, and lung involvement during treatment and follow-up. To assess the predictive value of D-dimer, receiver operating characteristic (ROC) analysis was conducted.
RESULTS: D-dimer elevation (> 243 ng/ml) was detected in 63.3% (76/120) of the patients. The mean D-dimer value was calculated as 3144.50 ± 1709.4 ng/ml (1643-8548) for inpatients with severe pneumonia in the intensive care unit. D-Dimer values showed positive correlations with age, duration of stay, lung involvement, fibrinogen, neutrophil count, neutrophil lymphocyte ratio (NLR) and platelet lymphocyte ratio (PLR). When the threshold D-dimer value was 370 ng/ml in the ROC analysis, this value was calculated to have 77% specificity and 74% sensitivity for lung involvement in patients with COVID-19.
CONCLUSION: D-Dimer levels in patients with COVID-19 correlate with outcome, but further studies are needed to see how useful they are in determining prognosis.
参考来源
- Ozen M, Yilmaz A, Cakmak V, et al. D-Dimer as a potential biomarker for disease severity in COVID-19. Am J Emerg Med. 2020. PMID: 33348224. doi:10.1016/j.ajem.2020.12.023
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。